Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2020-01-10 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2020
Director's Dealing
2020-01-10 English
Director's Dealing 2020
Director's Dealing
2020-01-10 English
Director's Dealing 2020
Director's Dealing
2020-01-10 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 27, 2019, reporting changes in the company's board of directors and appointments of new directors. It details the departure of a director and the appointment of two new directors, including their roles and compensation. There is no financial data or report content, only management and board changes. This fits the category of Board/Management Information (MANG). The document length is about 4976 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the classification is MANG with high confidence.
2020-01-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a short filing (3527 characters) reporting an event on December 10, 2019, specifically the issuance of a press release about a scientific presentation. There are no financial statements or detailed financial data included. The document primarily serves as a regulatory announcement of an event rather than a full financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-12-10 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which reports the departure of a director from the company's board. This matches the description of 'Board/Management Information' filings, which announce changes in the company's board of directors or senior management. The document is short (3122 characters) and contains specific information about a director's resignation, not a full report or financial data. Therefore, the appropriate classification is MANG (Board/Management Information).
2019-11-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.